Make sure you ask the question
About half of all postmenopausal women will have discomfort from
vaginal atrophy, with impacts on their well-being and quality of life.1,2
Women are reluctant to talk to their doctor about their symptoms.
Reasons women give for reluctance to discuss vaginal symptoms:3
About half of all postmenopausal women will have discomfort from vaginal atrophy, with impacts on their well-being and quality of life.1,2
Women are reluctant to talk to their doctor about their symptoms.
Reasons women give for reluctance to discuss vaginal symptoms:3
Only 10% of HCPs do
Even when women want accurate medical information about vaginal atrophy, they want their doctor to initiate the conversation.4 However, only 10% of healthcare professionals will ask about vaginal atrophy symptoms.5
You know that patients find it difficult to start a conversation about vaginal atrophy4, so you always ask about the symptoms.
Diagnosing vaginal atrophy may allow early management and treatment, intervening in a progressive condition that impacts her well-being and quality of life.2,6,7
You know that women can be reluctant to talk about their symptoms for a variety of reasons4, so you ask the question for them.
She will be glad
you asked
the question
My Blissel® Time to talk
Video Library
A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patients quality of life.
Book a virtual or face to face appointment
Consilient Health are committed to adding value to the NHS and our Healthcare Partnership Managers are trained on the clinical aspects of Blissel®. To book a virtual or face to face appointment, please complete the GDPR compliant form.
Ultra low dose estriol vaginal gel5,8
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com
1. Nappi RE. and Palacios S. Climacteric. 2014;17:3–9. 2. Moral E, et al. Menopause. 2018;25(12):1418-23. 3. Kagan R, et al. Drugs Aging. 2019;36:897–908. 4. Krychman M, et al. J Sex Med 2017;14:425-433. 5. Cano A, et al. Menopause. 2012;19(10):1130-9. 6. Cagnacci A, et al. Climacteric. 2019;22(1):85-89. 7. NAMS position statement. Menopause. 2020;27(9):976-92. 8. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.
Date of preparation: July 2025 | UK-BLS-43a(3)
